Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer.

Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D.

Cancers (Basel). 2019 Oct 15;11(10). pii: E1567. doi: 10.3390/cancers11101567. Review.

2.

Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.

Court F, Le Boiteux E, Fogli A, Müller-Barthélémy M, Vaurs-Barrière C, Chautard E, Pereira B, Biau J, Kemeny JL, Khalil T, Karayan-Tapon L, Verrelle P, Arnaud P.

Genome Res. 2019 Oct;29(10):1605-1621. doi: 10.1101/gr.249219.119. Epub 2019 Sep 18.

PMID:
31533980
3.

Prognostic significance of MEOX2 in gliomas.

Tachon G, Masliantsev K, Rivet P, Petropoulos C, Godet J, Milin S, Wager M, Guichet PO, Karayan-Tapon L.

Mod Pathol. 2019 Jun;32(6):774-786. doi: 10.1038/s41379-018-0192-6. Epub 2019 Jan 18.

PMID:
30659268
4.

Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases.

Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L, Tougeron D.

Cancers (Basel). 2018 Dec 10;10(12). pii: E504. doi: 10.3390/cancers10120504.

5.

Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51.

Tachon G, Cortes U, Guichet PO, Rivet P, Balbous A, Masliantsev K, Berger A, Boissonnade O, Wager M, Karayan-Tapon L.

Int J Mol Sci. 2018 Oct 3;19(10). pii: E3018. doi: 10.3390/ijms19103018.

6.

Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.

Guichet PO, Masliantsev K, Tachon G, Petropoulos C, Godet J, Larrieu D, Milin S, Wager M, Karayan-Tapon L.

J Pathol. 2018 Oct;246(2):205-216. doi: 10.1002/path.5133. Epub 2018 Aug 28.

PMID:
30009411
7.

Functional invadopodia formed in glioblastoma stem cells are important regulators of tumor angiogenesis.

Petropoulos C, Guichet PO, Masliantsev K, Wager M, Karayan-Tapon L.

Oncotarget. 2018 Apr 17;9(29):20640-20657. doi: 10.18632/oncotarget.25045. eCollection 2018 Apr 17.

8.

Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.

Tachon G, Frouin E, Karayan-Tapon L, Auriault ML, Godet J, Moulin V, Wang Q, Tougeron D.

Eur J Cancer. 2018 May;95:112-116. doi: 10.1016/j.ejca.2018.01.087. Epub 2018 Mar 5. No abstract available.

PMID:
29519639
9.

Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome.

Masliantsev K, Pinel B, Balbous A, Guichet PO, Tachon G, Milin S, Godet J, Duchesne M, Berger A, Petropoulos C, Wager M, Karayan-Tapon L.

Oncotarget. 2017 Dec 16;9(3):3968-3979. doi: 10.18632/oncotarget.23374. eCollection 2018 Jan 9.

10.

Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.

Thiebault Q, Defossez G, Karayan-Tapon L, Ingrand P, Silvain C, Tougeron D.

BMC Cancer. 2017 Nov 14;17(1):765. doi: 10.1186/s12885-017-3759-6.

11.

Association between clinicopathological characteristics and RAS mutation in colorectal cancer.

Rimbert J, Tachon G, Junca A, Villalva C, Karayan-Tapon L, Tougeron D.

Mod Pathol. 2018 Mar;31(3):517-526. doi: 10.1038/modpathol.2017.119. Epub 2017 Oct 20.

12.

Crizotinib targets in glioblastoma stem cells.

Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L.

Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27.

13.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

14.

Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.

Pinel B, Duchesne M, Godet J, Milin S, Berger A, Wager M, Karayan-Tapon L.

J Neurooncol. 2017 Apr;132(2):287-294. doi: 10.1007/s11060-016-2367-7. Epub 2017 Jan 10.

PMID:
28070830
15.

SETMAR isoforms in glioblastoma: A matter of protein stability.

Dussaussois-Montagne A, Jaillet J, Babin L, Verrelle P, Karayan-Tapon L, Renault S, Rousselot-Denis C, Zemmoura I, Augé-Gouillou C.

Oncotarget. 2017 Feb 7;8(6):9835-9848. doi: 10.18632/oncotarget.14218.

16.

High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.

Jeantet M, Tougeron D, Tachon G, Cortes U, Archambaut C, Fromont G, Karayan-Tapon L.

Int J Mol Sci. 2016 Dec 1;17(12). pii: E2015.

17.

[Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer].

Soria JC, Bastian G, Bolotine L, Calais G, Céraline J, de Cremoux P, Espié M, Karayan-Tapon L, Laprie A, Mazeron JJ, Négrier S, Roché H.

Bull Cancer. 2016 Sep;103(9):719-29. doi: 10.1016/j.bulcan.2016.07.004. Epub 2016 Aug 23. French. No abstract available.

PMID:
27561824
18.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

19.

A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.

Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L.

BMC Cancer. 2016 Aug 5;16:604. doi: 10.1186/s12885-016-2647-9.

20.

Absence of IDH mutation in colorectal cancers with microsatellite instability.

Tougeron D, Guilloteau K, Karayan-Tapon L.

Dig Liver Dis. 2016 Jun;48(6):681-3. doi: 10.1016/j.dld.2016.02.019. Epub 2016 Mar 2.

PMID:
26987944
21.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A.

J Natl Cancer Inst. 2016 Feb 1;108(7). doi: 10.1093/jnci/djv438. Print 2016 Jul.

PMID:
26839356
22.

The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.

Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, Arnaud P.

Carcinogenesis. 2016 Feb;37(2):169-176. doi: 10.1093/carcin/bgv251. Epub 2015 Dec 30.

PMID:
26717998
23.

Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.

Cortes U, Guilloteau K, Rouvreau M, Archaimbault C, Villalva C, Karayan-Tapon L.

Exp Mol Pathol. 2015 Oct;99(2):207-11. doi: 10.1016/j.yexmp.2015.07.003. Epub 2015 Jul 8.

PMID:
26163758
24.

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Lecomte T; Association des Gastro-Entérologues Oncologues (AGEO).

Eur J Cancer. 2015 May;51(8):925-34. doi: 10.1016/j.ejca.2015.03.011. Epub 2015 Apr 8.

PMID:
25864037
25.

IL22/IL-22R pathway induces cell survival in human glioblastoma cells.

Akil H, Abbaci A, Lalloué F, Bessette B, Costes LM, Domballe L, Charreau S, Guilloteau K, Karayan-Tapon L, Bernard FX, Morel F, Jauberteau MO, Lecron JC.

PLoS One. 2015 Mar 20;10(3):e0119872. doi: 10.1371/journal.pone.0119872. eCollection 2015.

26.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.

PLoS One. 2014 Sep 18;9(9):e104455. doi: 10.1371/journal.pone.0104455. eCollection 2014.

27.

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L.

Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22.

28.

Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.

Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, Taillandier L.

Eur J Cancer. 2014 Sep;50(13):2364-6. doi: 10.1016/j.ejca.2014.06.001. Epub 2014 Jul 3. No abstract available.

PMID:
24999209
29.

A mesenchymal glioma stem cell profile is related to clinical outcome.

Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, Chomel JC, Karayan-Tapon L.

Oncogenesis. 2014 Mar 17;3:e91. doi: 10.1038/oncsis.2014.5.

30.

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.

Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L, Mosser J, Ichimura K, Figarella-Branger D.

J Neurooncol. 2014 Feb;116(3):487-96. doi: 10.1007/s11060-013-1332-y. Epub 2014 Jan 14.

31.

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.

Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L.

Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.

32.

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L.

Cancer Chemother Pharmacol. 2013 Aug;72(2):397-403. doi: 10.1007/s00280-013-2211-0. Epub 2013 Jun 14.

PMID:
23765179
33.

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.

Tougeron D, Lecomte T, Pagès JC, Villalva C, Collin C, Ferru A, Tourani JM, Silvain C, Levillain P, Karayan-Tapon L.

Ann Oncol. 2013 May;24(5):1267-73. doi: 10.1093/annonc/mds620. Epub 2013 Jan 4.

PMID:
23293113
34.

O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.

Int J Mol Sci. 2012;13(6):6983-94. doi: 10.3390/ijms13066983. Epub 2012 Jun 7.

35.

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.

Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D.

Cancer. 2012 Sep 1;118(17):4201-11. doi: 10.1002/cncr.27392. Epub 2012 Jan 31.

36.

Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells.

Cheray M, Petit D, Forestier L, Karayan-Tapon L, Maftah A, Jauberteau MO, Battu S, Gallet FP, Lalloué F.

Cancer Lett. 2011 Dec 15;312(1):24-32. doi: 10.1016/j.canlet.2011.07.027. Epub 2011 Aug 6.

PMID:
21899947
37.

Altered expression of the gap junction protein connexin43 is associated with papillary thyroid carcinomas when compared with other noncancer pathologies of the thyroid.

Dominguez C, Karayan-Tapon L, Desurmont T, Gibelin H, Crespin S, Fromont G, Levillain P, Bouche G, Cantereau A, Mesnil M, Kraimps JL.

Thyroid. 2011 Oct;21(10):1057-66. doi: 10.1089/thy.2011.0041. Epub 2011 Aug 29.

PMID:
21875346
38.

An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.

Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, Marie Y, Rickman D, Thomas E, Delattre JY, Honnorat J, Sanson M, Berger F.

Mol Cancer. 2010 Sep 7;9:234. doi: 10.1186/1476-4598-9-234.

39.

STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?

Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, Tourani JM, Dusanter-Fourt I, Turhan AG, Karayan-Tapon L.

Int J Cancer. 2011 Feb 15;128(4):826-38. doi: 10.1002/ijc.25416.

40.

Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.

Fontaine JF, Mirebeau-Prunier D, Raharijaona M, Franc B, Triau S, Rodien P, Goëau-Brissonniére O, Karayan-Tapon L, Mello M, Houlgatte R, Malthiery Y, Savagner F.

PLoS One. 2009 Oct 29;4(10):e7632. doi: 10.1371/journal.pone.0007632.

41.

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.

Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Ré C.

J Neurooncol. 2010 May;97(3):311-22. doi: 10.1007/s11060-009-0031-1. Epub 2009 Oct 20.

PMID:
19841865
42.

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?

Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J.

Br J Cancer. 2008 Oct 7;99(7):1153-60. doi: 10.1038/sj.bjc.6604641. Epub 2008 Sep 9.

43.

[Molecular biology of adult gliomas: some landmarks for neurosurgeons].

Wager M, Fontaine D, Karayan-Tapon L.

Neurochirurgie. 2008 Aug;54(4):529-44. doi: 10.1016/j.neuchi.2008.04.002. Epub 2008 Jun 30. Review. French.

PMID:
18586283
44.

Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study.

Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, Blanc JL, Lapierre F, Rigoard P, Milin S, Duthe F, Bonneau D, Larsen CJ, Karayan-Tapon L.

Br J Cancer. 2008 Jun 3;98(11):1830-8. doi: 10.1038/sj.bjc.6604378. Epub 2008 May 27.

45.

The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Ferru A, Fromont G, Gibelin H, Guilhot J, Savagner F, Tourani JM, Kraimps JL, Larsen CJ, Karayan-Tapon L.

Br J Cancer. 2006 Dec 18;95(12):1670-7. Epub 2006 Nov 21.

46.

Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.

Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ, Karayan-Tapon L.

Br J Cancer. 2006 Oct 23;95(8):1062-9.

47.

Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours.

Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, Larsen CJ, Karayan-Tapon L.

Eur J Surg Oncol. 2006 Mar;32(2):228-30. Epub 2005 Nov 14.

PMID:
16290057
48.

Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ, Karayan-Tapon L.

J Neurooncol. 2004 Jul;68(3):275-83.

PMID:
15332332
49.

Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas.

Karayan-Tapon L, Menet E, Guilhot J, Levillain P, Larsen CJ, Kraimps JL.

Eur J Surg Oncol. 2004 Feb;30(1):73-9.

PMID:
14736527

Supplemental Content

Loading ...
Support Center